MCO Molecular and Clinical Oncology 2049-9450 2049-9469 D.A. Spandidos 10.3892/mco.2019.1876 MCO-0-0-1876 Articles Circulating miR-141-3p, miR-143-3p and miR-200c-3p are differentially expressed in colorectal cancer and advanced adenomas ArdilaHéctor Javier 1 2 Sanabria-SalasMaría Carolina 1 MenesesXimena 3 RiosRafael 4 Huertas-SalgadoAntonio 5 SerranoMartha Lucía 1 6 Grupo de Investigación en Biología del Cáncer, Instituto Nacional de Cancerología, Bogotá, Colombia Instituto de Genética, Facultad de Medicina, Universidad Nacional de Colombia, Bogotá, Colombia Unidad de Análisis, Instituto Nacional de Cancerología, Bogotá, Colombia Unidad de Genética y Resistencia Antimicrobiana, Centro Internacional de Genómica Microbiana, Universidad el Bosque, Bogotá, Colombia Banco Nacional de Tumores Terry Fox, Instituto Nacional de Cancerología, Bogotá, Colombia Departamento de Química, Facultad de Ciencias, Universidad Nacional de Colombia, Bogotá, Colombia Correspondence to: Professor Martha Lucía Serrano, Departamento de Química, Facultad de Ciencias, Universidad Nacional de Colombia, Avenue Carrera 30 45-03, Edificio 451, Oficina 326, Bogotá, Colombia, E-mail: mlserranol@unal.edu.co 08 2019 11 06 2019 11 2 201 207 20062018 22042019 Copyright © 2019, Spandidos Publications 2019

Colorectal cancer (CRC) is one of the prominent causes of cancer related deaths because, in part, there is not an early, non-invasive, effective detection strategy. Circulating microRNAs (miRNAs) have been proposed as potential non-invasive biomarkers for CRC. In this study, we evaluated the miRNA profile in sixteen CRC tissues by Next-Generation-Sequencing and compared the circulating expression levels of 22 miRNAs among 45 CRC, 14 hyperplastic polyps, 11 advanced adenoma patients and 45 control subjects, by reverse transcription-quantitative PCR, to search for miRNAs which could be potential biomarkers. In total, nine of them represented 70% of total read counts (miR-10a-5p, miR-192-5p, miR-10b-5p, miR-22-3p, miR-26a-5p, miR-148a-3p, miR-181a-5p, miR-92a-3p and miR-143-5p). In silico analysis found eight candidates to mature miRNAs. With respect to circulating miRNA, we found higher serum expression levels of miR-143-3p, miR-141-3p and miR-200c-3p in the CRC and adenoma groups compared with controls (P<0.002), and we also found significant higher levels of miR-141-3p and miR-200c-3p in serum of adenoma patients compared with the CRC group. In conclusion, the measurement of miRNAs in the blood could complement current screening methods for CRC and might provide new insights into mechanisms of tumorigenesis. miR-143-3p, miR-141-3p and miR-200c-3p could be interesting miRNAs to study as potential biomarkers for CRC.

 microRNA cancer biomarker colorectal neoplasms adenomas signal pathway Introduction

Globally, colorectal cancer (CRC) is the second most common cancer in women and the third most common in men (1). Although the treatments are improved for CRC, increasing the 5-year survival rate, the overall estimated death rate is still 50–60% (2). There is not a good method to diagnose for this cancer, because although tumor markers greatly improve it, the invasive nature of current procedures, as colonoscopy, limits their application. Identification of useful non-invasive biomarkers in order to facilitate the correct diagnosis and treatment is critical to improve patient survival.

MicroRNAs (miRNAs) are a type of small RNA (18–22 nucleotides, nt) that mediates post-transcriptional gene silencing by binding to mRNAs. The role of miRNA in carcinogenesis has been increasingly recognized; miRNAs affect many oncogenes and tumor suppressor genes. miRNA-induced deregulation in CRC has been well documented and for this reason, those could be exploited as biomarkers in CRC due to its high tissue specificity, stability and the differences in the expression level between normal and tumor tissues (3–6). The detection of miRNAs in serum samples has raised the possibility that they could be used as non-invasive biomarkers for different types of cancer (7–9).

In our study, we evaluated the miRNA profile in 16 samples of tumor tissue from patients with CRC by next-generation sequencing (NGS) and compared the expression levels of 22 miRNAs between CRC, hyperplastic polyps and adenoma patients with control subjects to search differences that could be useful for a better understanding of CRC carcinogenesis and could be potential biomarkers.

 Patients and methods <sec> <title>Subjects

We included 45 CRC cases (24 colon cancer and 21 rectum cancer), 11 advanced adenomas, 14 hyperplastic polyps and 48 controls from a multicenter hospital-based case-control study conducted in Colombia. All cases were incident and confirmed by histopathology, while controls were individuals without gastrointestinal symptoms attending the outpatient services of primary care units. Advanced adenomas were adenomas with size ≥1 cm, tubulovillous or villous adenomas or with high-grade dysplasia. Subjects were unrelated and their age ranged between 30 and 76 years. Neither cases nor controls had a personal history of other cancers and received neither chemotherapy nor radiotherapy. Trained health professionals collected blood samples and administered structured questionnaires on socio-economic characteristics and other risk factors, once each participant gave written informed consent. Tissues were collected during colonoscopy. This study was approved by the Ethics Committee of the Instituto Nacional de Cancerología, Bogotá, Colombia and by all the other Ethical Boards from participant health institutions upon request.

 miRNAs isolation and quantification

Total RNA was extracted from 10 mg of tumor tissue using Trizol (Thermo Fisher Scientific, Whaltan, USA) and after that, miRCURY™ RNA Isolation Kit–Tissue (Exiqon, Copenhagen, Denmark) was used for miRNA isolation. Serum miRNAs were extracted from 200 µl using miRCURY RNA Isolation Kit-Biofluids (Exiqon, Copenhagen, Denmark). Concentration and quality of the samples was assessed using Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, California, USA) and Qubit 3.0 Fluorometer (Thermo Fisher Scientific, Whaltan, USA), following the manufacturer's instructions. Isolated RNA was stored at −80°C until use.

 Libraries construction and sequencing

Libraries were constructed from 1 µg of extracted miRNAs using Truseq Small RNA kit (Illumina, San Diego, USA), following manufacturer's instructions. A pool of 16 libraries was obtained with an adjusted concentration of 10 nM in a final volume of 100 µl. The final concentration of the pooled samples was 2 nM. The sequencing was performed in a MiSeq, using MiSeq Reagent Kit v2 (Illumina®, San Diego, USA), following the manufacturer's instructions.

 Bioinformatics analysis of detected miRNAs

Bioinformatics analysis was made following the pipeline from Hackenberg et al and the tool miRanalyzer (10). The reads shorter than 17 nt and longer than 26 nt were discard. Selected reads were aligned against different databases, including the RefSeq to detect mRNA, the miRBase database (11) to detect mature miRNAs, and the GRCh37 human reference genome assembly to predict possible new miRNAs. The miRanalyzer tool also does a prediction over candidate miRNAs. We also took into account the following high confidence criteria to select novel miRNA sequence defined by miRbase (11).

 Expression levels of selected miRNA in serum and tumor tissue

The Universal cDNA synthesis kit II (Exiqon®, Copenhagen, Denmark) was used for reverse transcription (RT), according to the manufacturer's instructions. The UniSp6 RNA Spike-in control was added during the cDNA synthesis. For quantitative PCR, the obtained cDNA was diluted 1:100 in nuclease free water and then 5 µl of cDNA along with 5 µl of Exilent SYBR Green master mix were transferred to a custom-made Pick & Mix microRNA PCR panel that included primers for 22 target miRNAs (Exiqon®, Copenhagen, Denmark). These miRNAs were selected based on the abundance of reads found in the tumor tissue libraries and others by literature review of the most abundant in serum from CRC patients. The hsa-miR were: 10a-5p, 10b-5p, 192-5p, 22-3p, 26a-5p, 148a-3p, 92a-3p, 143-3p, 486-5p, 141-3p, 27b-3p, 29a-3p, 221-3p, 200c-3p, 145-5p, 423-3p, 155-5p, 223-3p, 320a, 21-5p, 20a-5p and 221-3p. Amplification was performed in duplicates in a Light Cycler 480 Real-Time PCR System (Roche, Basel, Switzerland). Amplification curves were analyzed using the Roche LC software, both for determination of Ct values and for melting curve analysis. Normality of miRNA levels was assessed by Shapiro-Wilks test. Correlations between serum and tissue levels were made using Pearson test.

 Data analysis and normalization of RT-PCR

Amplification efficiency was calculated by using Exiqon GenEx software specifically adapted to miRCURY LNA™ Universal RT microRNA PCR products, following the manufacturer's instructions. First, we made a pre-processing and normalization of our data in GenEx. Only miRNAs detected with Ct <37 were included for analysis. During quality control steps, samples with a >50% of missing data and miRNAs with <40% of valid data were excluded. The software selected the hsa-miR-92a-3p as reference gene for normalization. This normalization step correspond to the first delta Ct, namely delta to the normalization factor, of the 2−ΔΔCt method (12). After that, the serum Ct from polyps, adenomas and CRC patients were converted to relative quantities, comparing to control group, and by this step the data was expressed completely as N=2−ΔΔCt method (12). Expression data was converted to log2 scale for further analysis. Comparisons between groups in serum samples were done by Welch's ANOVA method adjusted by sex and differential expressed genes were identified based on a Bonferroni corrected P-value of <0.002 (alpha of 0.05/22 tests). Finally, we used Pearson correlation analysis of the miRNAs expression values found in serum and tumor of CRC samples.

 Bioinformatics analysis of target genes for detected miRNAs and related biological pathways

In order to determine target genes of the identified miRNAs, we used DIANA-TarBase v7.0 (13), that predict molecular targets of miRNAs in coding sequences 3′UTR. Related biological pathways associated with target genes and miRNAs were made using the Kyoto Encyclopedia of Genes and Genomes (KEEG) (14).

 Results Libraries in tumor CRC Expression pattern of known miRNAs

Sixteen tumor samples were assessed by NGS, five correspond to colon cancer and eleven to rectal cancer, 60% were from males and the mean age was 59,1 years. 763 known mature miRNAs were detected in the sixteen libraries by at least one alignment in miRBase (11). The read counts of the mature miRNAs from sixteen libraries were pooled. The known mature miRNAs showed a wide range of expression values spanning from 1 to 222455 read counts. 176 of 763 known miRNAs detected had only one read count and 167 had more than 100 read counts. Nine miRNAs had expression levels above 2% and it represents 70.4% of the total read counts (hsa-miR: 10a-5p, 192-5p, 10b-5p, 22-3p, 26a-5p, 148a-3p, 181a-5p, 92a-3p and 143-5p) (Table IA).

 Prediction and expression levels of potential novel miRNAs

In total, eight potential novel miRNAs with fuzzy Dicer pattern were identified in the libraries; no potential novel miRNA was detected with a perfect Dicer pattern. Seven candidates were present in four or more libraries. In silico analysis of these sequences against miRBase, led to identify that each of these candidates had a partial or total complementarity with mature miRNAs (Table II).

 Pathways related with most common found miRNAs

We did a search of gene targets and pathways related of the nine most common miRNAs found by sequencing in the ‘Colorectal cancer pathway’ (hsa05210) in TarBase 7.0/KEGG (13). We found that all of these miRNAs had gene targets involved in different pathways related with CRC. The most common pathways involved are WNT, MAPK, PI3K/Akt, TGF-β, DCC, p53 and microsatellite instability (MSI).

 miRNAs levels in serum

From the most abundant miRNAs detected by sequencing in tumor tissue, along with others thirteen differentially expressed in serum from CRC patients according to literature (Table IB), we selected 22 miRNAs to be analysed by RT-PCR in the serum of patients including 45 CRC, 11 advanced adenomas, 14 hyperplastic polyps and 48 controls were enrolled in this study. Table III shows the distribution of age and gender according to phenotype. Pre-processing data, using Exiqon GenEx software, excluded six serum samples because they had >50% of missing data. Table I shows the percentage of total read counts, by NGS in sixteen samples, of the thirteen miRNAs selected according to literature.

From the twenty-two miRNAs selected to evaluate differences in their levels in serum between groups, pre-processing data excluded two miRNAs (miR-10a-5p and miR-221-5p) because they had <40% of valid data. The data was expressed completely as N=2−ΔΔCt method, miR-92-3p was selected by GenEx as reference gene for normalization. Among the remaining 19 miRNAs, we found significant higher serum expression levels of miR-143-3p, miR-141-3p and miR-200c-3p in the CRC and adenoma groups compared to controls by Mann-Whitney test with Bonferroni corrected P-value (P<0.002; Fig. 1). In addition, we also found significant higher levels of miR-141-3p and miR-200c-3p in serum of adenoma patients compared to CRC group (P<0.002).

Other miRNAs did not show statistical significant differences between CRC patients and controls. Serum miRNA levels between polyps patients and controls were very similar and their behavior were the same. We also assessed levels of miRNAs in the available twenty-two tumor tissues of CRC patients by RT-PCR. None of the correlations in levels of miR-143-3p, miR-141-3p and miR-200c, between tissue and serum samples from CRC patients assessed Pearson test by were significant (P=0.225, P=0.867 and P=0.652 respectively) (data not shown). Sixteen tumor samples used for NGS were assessed by RT-PCR and their corresponding serum samples too.

We used DIANA-miRPath v.3, to evidence the involvement of these three miRNAs in the CRC pathway (hsa05210) (15). This analysis led to identify many gene targets related with different pathways, such as: Apoptosis, PI3K-Akt, Wnt, MSI and TGF-β (Table IV).

 Discussion

In the present work, deep sequencing and RT-qPCR were used to analyze the expression levels of miRNAs in tumor tissue and serum from patients with CRC. By deep sequencing, this study detects 763 mature miRNAs in CRC tissues from sixteen patients. Of the nine most expressed miRNA in our samples, three, miR-10b-5p, −26a-5p and −92a-3p, have been reported that can act as oncomiRs (6,16–28), three, miR-192-5p, miR-148a-3p and miR-143-3p behave like anti-oncomiRs (6,17,29–37). With respect to miR-10a-5p, miR-22-3p and miR-181a-5p, their tumorigenesis role is inconsistent. These miRNAs with dual roles in carcinogenesis prove that many targets from many pathways can be regulated by one miRNA and their effect on expression is very complex at cellular and tisular levels.

One advantage of miRNA studies by deep sequencing is that this technique allows the detection of novel miRNAs. Our analysis found eight new miRNA candidates. All candidates showed partial or total complementarity with mature miRNAs (scores 90–105) based on miRBase analysis. These sequences with some grade or total complementary could be produced by miRNAs bidirectional transcription and processing (38,39). It is possible that miRNA:miRNA duplex can be formed in the cell, operating in competition with each other. Further experimental studies are needed in order to assess the role of these miRNA candidates in colorectal carcinogenesis, before register them into public databases such as miRBase.

We found three miRNAs with significantly higher expression in serum of CRC patients vs. controls (i.e. miR-143-3p, miR-141-3p and miR-200c-3p) and two of them were more expressed in patients with adenomas compared those with CRC (i.e. miR-141-3p and miR-200c-3p). Interestingly, miR-141-3p and miR-200c-3p derive from the same precursor, miR-8. Serum miR-141-3p and miR-200c-3p was found over expressed in CRC patients compared to controls, as previously reported (40–47). We found that patients with adenomas had the highest serum levels of miR-141-3p and miR-200c-3p, compared to all the others (i.e., controls, polyps and CRC groups). These two miRNAs are good candidates for CRC screening and prevention, as they could be measured through minimally invasive procedures; nevertheless, further population-based studies are needed for validation purposes.

The results seem to be contradictory. On the one hand, lower levels of miRNAs have been found in CRC (18,48–53). On the other hand, our findings are consistent with Luo et al study (54) regarding higher levels of miR-143-3p in CRC patients. The role of miRNAs in cancer is very complex and depends of many particular factors and not alone cancer type. Differences found in various studies in circulating levels of miRNA can be related with ethnicity, gender and technical variance, but there are other confounding lifestyle factors, such as smoking, physical activity, etc., that are hardly verifiable and correctly taken into consideration (9).

Like Waters et al (55), we did not find any correlation of miRNA levels between serum and tissue of cancer patients. The absence of this correlation could be attributed to the complex nature of the circulating miRNAs sources. It has been found that circulating tumor cells and exosomal release from tumor cells contribute to circulating miRNAs (56,57). Also, other factors such as the host immune response or inflammation, could modulate miRNAs circulation levels and cause these levels to be different to from those of the tissues. Therefore, the levels of miRNA in circulation not only reflect what happens in the tumor tissue, but also show what happens in the whole human body.

Pathway analysis of the target genes of these miRNAs uncovered a significant number of genes involved in many CRC pathways, in accordance with reports highlighting that the hallmark feature of CRC is the hyperactivation of the WNT pathway, usually caused by mutations in the tumor suppressor gene APC (~75% of all tumors) (58), mutations in CTNNB1 (β-catenin), or in other Wnt signaling activators (59–61).

In conclusion, this study found 763 miRNAs in tissue from CRC and eight candidates to novel miRNAs. In serum, we found that three miRNAs, miR-141-3p, miR-143-3p and miR-200c-3p, were significantly higher in CRC vs. controls, and that two of them, miR-141-3p and miR-200c, were also significantly lower in CRC vs. adenomas. The measurement of miRNAs in the blood could complement current screening methods for CRC and might provide new insights into mechanisms of tumorigenesis and metastasis. However, the differences between studies highlight the necessity to perform further investigation.

 Acknowledgements

The authors would like to thank Dr Ivan Lesende (Universidad de la Coruña-Spain) for his technical support with the library construction, Gustavo Hernández (Instituto Nacional de Cancerología, Bogotá, Colombia) for collaboration with statistical analysis and Unidad de Genética y Resistencia Antimicrobiana, Centro Internacional de Genómica Microbiana for made sequencing.

 Funding

The present study was supported by Instituto Nacional de Cancerología-E.S.E. de Colombia (DNP code 41030610-592) y la Universidad Nacional de Colombia-Sede Bogotá (Hermes code 23561/QUIPU code 201010022022).

 Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

 Authors' contributions

HJA wrote the protocol, performed experiments and contributed to the writing of the manuscript. MCS analyzed and interpreted the data, and wrote the manuscript. XM conducted the statistical analysis and contributed to the writing of the manuscript. RR performed the bioinformatics analysis and contributed to the writing of the manuscript. AHS contribute to the design of the protocol, the analysis and interpretation of the data, and the writing of the manuscript. MLS contributed to the design of the protocol, performed the experiments and was a major contributor in writing the manuscript. All authors read and approved the final manuscript.

 Ethics approval and consent to participate

The present study was approved by the Ethics Committee of the Instituto Nacional de Cancerología, Bogotá, Colombia and by all the other Ethical Boards from participant health institutions upon request. Each participant gave written informed consent.

 Patient consent for publication

Not applicable.

 Competing interests

The authors declare that they have no competing interests.

 References FerlayJSoerjomataramIDikshitREserSMathersCRebeloMParkinDMFormanDBrayFCancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012Int J Cancer136E359E386201510.1002/ijc.2921025220842 KumarRPriceTJBeekeCJainKPatelGPadburyRYoungGPRoderDTownsendABishnoiSKarapetisCSColorectal cancer survival: An analysis of patients with metastatic disease synchronous and metachronous with the primary tumorClin Colorectal Cancer138793201410.1016/j.clcc.2013.11.00824373733 CekaiteLEidePWLindGESkotheimRILotheRAMicroRNAs as growth regulators, their function and biomarker status in colorectal cancerOncotarget764766505201610.18632/oncotarget.639026623728 ChiYZhouDMicroRNAs in colorectal carcinoma-from pathogenesis to therapyJ Exp Clin Cancer Res3543201610.1186/s13046-016-0320-426964533 YiRLiYWangFLMiaoGQiRMZhaoYYMicroRNAs as diagnostic and prognostic biomarkers in colorectal cancerWorld J Gastrointest Oncol8330340201610.4251/wjgo.v8.i4.33027096028 SlatteryMLHerrickJSPellattDFStevensJRMullanyLEWolffEHoffmanMDSamowitzWSWolffRKMicroRNA profiles in colorectal carcinomas, adenomas and normal colonic mucosa: Variations in miRNA expression and disease progressionCarcinogenesis37245261201610.1093/carcin/bgv24926740022 MitchellPSParkinRKKrohEMFritzBRWymanSKPogosova-AgadjanyanELPetersonANoteboomJO'BriantKCAllenACirculating microRNAs as stable blood-based markers for cancer detectionProc Natl Acad Sci USA1051051310518200810.1073/pnas.080454910518663219 ChenXBaYMaLCaiXYinYWangKGuoJZhangYChenJGuoXCharacterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseasesCell Res189971006200810.1038/cr.2008.28218766170 TiberioPCallariMAngeloniVDaidoneMGAppiertoVChallenges in using circulating miRNAs as cancer biomarkersBiomed Res Int2015731479201510.1155/2015/73147925874226 HackenbergMRodríguez-EzpeletaNAransayAMmiRanalyzer: An update on the detection and analysis of microRNAs in high-throughput sequencing experimentsNucleic Acids Res 39 (Web Server issue)W132W138201110.1093/nar/gkr247 KozomaraAGriffiths-JonesSmiRBase: Annotating high confidence microRNAs using deep sequencing dataNucleic Acids Res 42 (Database Issue)D68D73201410.1093/nar/gkt1181 LivakKJSchmittgenTDAnalysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) methodMethods25402408200110.1006/meth.2001.126211846609 VlachosISParaskevopoulouMDKaragkouniDGeorgakilasGVergoulisTKanellosIAnastasopoulosILManiouSKarathanouKKalfakakouDDIANA-TarBase v7.0: Indexing more than half a million experimentally supported miRNA:mRNA interactionsNucleic Acids Res 43 (Database Issue)D153D159201510.1093/nar/gku1215 KanehisaMGotoSKEGG: Kyoto encyclopedia of genes and genomesNucleic Acids Res282730200010.1093/nar/28.1.2710592173 VlachosISZagganasKParaskevopoulouMDGeorgakilasGKaragkouniDVergoulisTDalamagasTHatzigeorgiouAGDIANA-miRPath v3.0: Deciphering microRNA function with experimental supportNucleic Acids Res43W460W466201510.1093/nar/gkv40325977294 ScheeKLorenzSWorrenMMGüntherCCHoldenMHovigEFodstadOMeza-ZepedaLAFlatmarkKDeep sequencing the MicroRNA transcriptome in colorectal cancerPLoS One8e66165201310.1371/journal.pone.006616523824282 Della Vittoria ScarpatiGCaluraEDi MarinoMRomualdiCBeltrameLMalapelleUTronconeGDe StefanoAPepeSDe PlacidoSAnalysis of differential miRNA expression in primary tumor and stroma of colorectal cancer patientsBiomed Res Int2014840921201410.1155/2014/84092125143946 MotoyamaKInoueHTakatsunoYTanakaFMimoriKUetakeHSugiharaKMoriMOver- and under-expressed microRNAs in human colorectal cancerInt J Oncol3410691075200919287964 HurKToiyamaYSchetterAJOkugawaYHarrisCCBolandCRGoelAIdentification of a metastasis-specific MicroRNA signature in human colorectal cancerJ Natl Cancer Inst107dju492201510.1093/jnci/dju49225663689 NishidaNYamashitaSMimoriKSudoTTanakaFShibataKYamamotoHIshiiHDokiYMoriMMicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cellsAnn Surg Oncol1930653071201210.1245/s10434-012-2246-122322955 WangYLiZZhaoXZuoXPengZmiR-10b promotes invasion by targeting HOXD10 in colorectal cancerOncol Lett12488494201610.3892/ol.2016.462827347170 Abdelmaksoud-DammakRChamtouriNTrikiMSaadallah-KallelAAyadiWCharfiSKhabirAAyadiLSallemi-BoudawaraTMokdad-GargouriROverexpression of miR-10b in colorectal cancer patients: Correlation with TWIST-1 and E-cadherin expressionTumour Biol391010428317695916201710.1177/101042831769591628345456 StrubbergAMMadisonBBMicroRNAs in the etiology of colorectal cancer: Pathways and clinical implicationsDis Model Mech10197214201710.1242/dmm.02744128250048 QianXZhaoPLiWShiZMWangLXuQWangMLiuNLiuLZJiangBHMicroRNA-26a promotes tumor growth and angiogenesis in glioma by directly targeting prohibitinCNS Neurosci Ther19804812201323870455 VishnubalajiRHamamRAbdullaMHMohammedMAKassemMAl-ObeedOAldahmashAAlajezNMGenome-wide mRNA and miRNA expression profiling reveal multiple regulatory networks in colorectal cancerCell Death Dis6e1614201510.1038/cddis.2014.55625611389 JinushiTShibayamaYKinoshitaIOizumiSJinushiMAotaTTakahashiTHoritaSDosaka-AkitaHIsekiKLow expression levels of microRNA-124-5p correlated with poor prognosis in colorectal cancer via targeting of SMC4Cancer Med315441552201410.1002/cam4.30925081869 PellattDFStevensJRWolffRKMullanyLEHerrickJSSamowitzWSlatteryMLExpression profiles of miRNA subsets distinguish human colorectal carcinoma and normal colonic mucosaClin Transl Gastroenterol7e152201610.1038/ctg.2016.1126963002 LvHZhangZWangYLiCGongWWangXMicroRNA-92a promotes colorectal cancer cell growth and migration by inhibiting KLF4Oncol Res23283290201610.3727/096504016X14562725373833 ChenYSongYWangZYueZXuHXingCLiuZAltered expression of MiR-148a and MiR-152 in gastrointestinal cancers and its clinical significanceJ Gastrointest Surg1411701179201010.1007/s11605-010-1202-220422307 TakahashiMCuatrecasasMBalaguerFHurKToiyamaYCastellsABolandCRGoelAThe clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancerPLoS One7e46684201210.1371/journal.pone.004668423056401 YangJMaDFeslerAZhaiHLeamniramitALiWWuSJuJExpression analysis of microRNA as prognostic biomarkers in colorectal cancerOncotarget85240352412201628881738 DongYYuJNgSSMicroRNA dysregulation as a prognostic biomarker in colorectal cancerCancer Manag Res6405422201425342918 HibinoYSakamotoNNaitoYGotoKOoHZSentaniKHinoiTOhdanHOueNYasuiWSignificance of miR-148a in colorectal neoplasia: Downregulation of miR-148a contributes to the carcinogenesis and cell invasion of colorectal cancerPathobiology82233241201510.1159/00043882626389729 YuBLiuXChangHMicroRNA-143 inhibits colorectal cancer cell proliferation by targeting MMP7Minerva Med1081319201727827523 HuYMaZHeYLiuWSuYTangZPART-1 functions as a competitive endogenous RNA for promoting tumor progression by sponging miR-143 in colorectal cancerBiochem Biophys Res Commun490317323201710.1016/j.bbrc.2017.06.04228619512 GuoHChenYHuXQianGGeSZhangJThe regulation of Toll-like receptor 2 by miR-143 suppresses the invasion and migration of a subset of human colorectal carcinoma cellsMol Cancer1277201310.1186/1476-4598-12-7723866094 SunGChengYWLaiLHuangTCWangJWuXWangYHuangYWangJZhangKSignature miRNAs in colorectal cancers were revealed using a bias reduction small RNA deep sequencing protocolOncotarget738573872201626646696 TylerDMOkamuraKChungWJHagenJWBerezikovEHannonGJLaiECFunctionally distinct regulatory RNAs generated by bidirectional transcription and processing of microRNA lociGenes Dev222636200810.1101/gad.161520818172163 LandgrafPRusuMSheridanRSewerAIovinoNAravinAPfefferSRiceAKamphorstAOLandthalerMA mammalian microRNA expression atlas based on small RNA library sequencingCell12914011414200710.1016/j.cell.2007.04.04017604727 WangJYWangCLWangXMLiuFJComprehensive analysis of microRNA/mRNA signature in colon adenocarcinomaEur Rev Med Pharmacol Sci2121142129201728537673 SunYLiuYCogdellDCalinGASunBKopetzSHamiltonSRZhangWExamining plasma microRNA markers for colorectal cancer at different stagesOncotarget71143411449201626863633 DingLYuLLHanNZhangBTmiR-141 promotes colon cancer cell proliferation by inhibiting MAP2K4Oncol Lett1316651671201710.3892/ol.2017.565328454307 XiYFormentiniAChienMWeirDBRussoJJJuJKornmannMJuJPrognostic values of microRNAs in colorectal cancerBiomark Insights2113121200618079988 ChenJWangWZhangYHuTChenYThe roles of miR-200c in colon cancer and associated molecular mechanismsTumour Biol3564756483201410.1007/s13277-014-1860-x24682933 ToiyamaYHurKTanakaKInoueYKusunokiMBolandCRGoelASerum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancerAnn Surg259735743201410.1097/SLA.0b013e3182a6909d23982750 HurKToiyamaYTakahashiMBalaguerFNagasakaTKoikeJHemmiHKoiMBolandCRGoelAMicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasisGut6213151326201310.1136/gutjnl-2011-30184622735571 ZhangGJZhouTLiuZLTianHPXiaSSPlasma miR-200c and miR-18a as potential biomarkers for the detection of colorectal carcinomaMol Clin Oncol1379384201310.3892/mco.2013.6124649179 MichaelMZO'ConnorSMvan Holst PellekaanNGYoungGPJamesRJReduced accumulation of specific microRNAs in colorectal neoplasiaMol Cancer Res1882891200314573789 SlabyOSvobodaMFabianPSmerdovaTKnoflickovaDBednarikovaMNenutilRVyzulaRAltered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancerOncology72397402200710.1159/00011348918196926 JiangXWangWYangYDuLYangXWangLZhengGDuanWWangRZhangXIdentification of circulating microRNA signatures as potential noninvasive biomarkers for prediction and prognosis of lymph node metastasis in gastric cancerOncotarget86513265142201729029418 LiDHuJSongHXuHWuCZhaoBXieDWuTZhaoJFangLmiR-143-3p targeting LIM domain kinase 1 suppresses the progression of triple-negative breast cancer cellsAm J Transl Res922762285201728559978 HeZYiJLiuXChenJHanSJinLChenLSongHMiR-143-3p functions as a tumor suppressor by regulating cell proliferation, invasion and epithelial-mesenchymal transition by targeting QKI-5 in esophageal squamous cell carcinomaMol Cancer1551201610.1186/s12943-016-0533-327358073 LiCYinYLiuXXiXXueWQuYNon-small cell lung cancer associated microRNA expression signature: Integrated bioinformatics analysis, validation and clinical significanceOncotarget82456424578201728445945 LuoXStockCBurwinkelBBrennerHIdentification and evaluation of plasma microRNAs for early detection of colorectal cancerPLoS One8e62880201310.1371/journal.pone.006288023690963 WatersPSMcDermottAMWallDHeneghanHMMillerNNewellJKerinMJDwyerRMRelationship between circulating and tissue microRNAs in a murine model of breast cancerPLoS One7e50459201210.1371/journal.pone.005045923226290 ValadiHEkströmKBossiosASjöstrandMLeeJJLötvallJOExosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cellsNat Cell Biol9654659200710.1038/ncb159617486113 Esquela-KerscherASlackFJOncomirs-microRNAs with a role in cancerNat Rev Cancer6259269200610.1038/nrc184016557279 Cancer Genome AtlasNetworkComprehensive molecular characterization of human colon and rectal cancerNature487330337201210.1038/nature1125222810696 LiuWDongXMaiMSeelanRSTaniguchiKKrishnadathKKHallingKCCunninghamJMBoardmanLAQianCMutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating beta-catenin/TCF signallingNat Genet26146147200010.1038/7985911017067 SuzukiHWatkinsDNJairKWSchuebelKEMarkowitzSDChenWDPretlowTPYangBAkiyamaYVan EngelandMEpigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancerNat Genet36417422200410.1038/ng133015034581 KooBKSpitMJordensILowTYStangeDEvan de WeteringMvan EsJHMohammedSHeckAJMauriceMMCleversHTumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptorsNature488665669201210.1038/nature1130822895187

Comparison of serum levels of miR-141-3p, miR-143-3p and miR-200c-3p among groups by box-whisker plots showing the median, first and third quartiles, and maximum and minimum values. *P<0.002, with mean significant differences among groups by a Mann-Whitney test with Bonferroni correction. Black circles indicate outliers. CRC, colorectal cancer; miR, microRNA.

Read count percentage of 22 miRNAs selected to be analyzed by reverse transcription-PCR.

A, miRNAs selected by abundance of reads found in the tumor tissue libraries
miRNA Read counts, %
10a-5p 22.45
192-5p 16.02
10b-5p 9.63
22-3p 4.80
26a-5p 4.70
148a-3p 4.69
181a-5p 2.99
92a-3p 2.98
143-3p 2.11
B, miRNAs selected by literature review
miRNA Read counts, %
486-5p 1.93
141-3p 1.50
27b-3p 1.45
29a-3p 0.33
221-3p 0.29
200c-3p 0.27
145-5p 0.10
423-3p 0.10
155-5p 0.09
320a 0.09
223-3p 0.08
21-5p 0.04
20a-5p 0.02

Location, cluster sequence and expression levels of miRNAs candidates found in the sixteen libraries of colorectal cancer tissues.

Full cluster genomic coordinates (build GRCh37) Alignments in miRBase
Chr Name Chr start Chr end Strand Read count Read cluster sequence Size (base) No. libraries Complementary to Score
1 cand_1.1 220291187 1102596 + 230 CTGTCAATTCATAGGTCA 18 1 miR-192-5p 90
3 cand_3.1 49057565 1102596 + 127 ACGGGAGTGATCGTGTCATT 20 8 miR-425-5p 100
5 cand_5.1 148808467 148808597 – 13 GAGATGCAGCACTGCACC 18 6 miR-143-3p 90
10 cand_10.1 104196251 104196359 – 5,920 GaCCTATGGAATTCAGTTCTCAGa 20–22 8 miR-146b-5p 105
cand_10.2 105154025 105154149 + 20 CGACCGACGCCACGCCGAGT 20 4 miR-1307-3p 100
cand_10.3 105154041 105154143 + 41 CCGGTCGAGGTCCGGTCGA 19 7 miR-1307-5p 95
17 cand_17.1 46657191 46657319 + 51 CCCTAGATACGAATTTG 17 9 miR-10a-3p 85
X cand_X.1 45605572 45605704 + 16 CCCAGCAGACAATGTAGCT 19 4 miR-221-3p 95

In Cand_10.1: In 64 read count the sequence does not have the first and last G, and in 1116.0 read count the sequence does not have the last G (IsomiRs). Chr, Chromosome; cand, candidate; No. Libraries, Number of libraries that include the candidate; Complementary to, Complementary to a mature miRNA, located in the opposite strand.

Characteristics of patients and controls enrolled in the present study.

Variables Control (n=48) Polyps (n=14) Adenoma (n=11) CRC (n=45)
Age (mean) 51.9 56.7 52.2 59.7
Male 58.3 35.7 45.5 53.3
Female 41.7 64.3 54.5 46.7
Colon cancer – – – 53.3%
Rectum cancer – – – 46.7%

CRC, colorectal cancer.

Gene targets and pathways regulated by hsa-miR-143-3p, hsa-miR-141-3p and hsa-miR-200c-3p in the colorectal cancer pathway (hsa-05210; from Diana Tool-miRPath v.3) (12).

Gene targets
Pathway hsa-miR-143-3p hsa-miR-141-3p hsa-miR-200c-3p
Apoptosis BCL2a BCL2a, BAX BCL2a
PI3K-Akt KRASa, AKT1, MAPK1 PIK3R1, RAC1, MAPK9 KRASa, RHOA, JUN
WNT None TCF7L1a, CCND1a, CTNNB1 TCF7L1a, TCF7L2, CCND1a, APC
MSI None MSH2 None
TGF-β None TGFB2 SMAD2

Gene targets identified in more than one of the three miRs. MSI, microsatellite instability; miR, microRNA.